Drug Repurposing in Oncology: Current Evidence and Future Direction

Curr Med Chem. 2021;28(11):2175-2194. doi: 10.2174/0929867327999200820124111.

Abstract

Background: Drug repurposing, the application of known drugs and compounds with a primary non-oncology purpose, might be an attractive strategy to offer more effective treatment options to cancer patients at a low cost and reduced time.

Methods: This review described a total of 10 kinds of non-oncological drugs from more than 100 mechanical studies as well as evidence from population-based studies. The future direction of repurposed drug screening is discussed by using patient-derived tumor organoids.

Results: Many old drugs showed previously unknown effects or off-target effects and can be intelligently applied for cancer chemoprevention and therapy. The identification of repurposed drugs needs to combine evidence from mechanical studies and population-based studies. Due to the heterogeneity of cancer, patient-derived tumor organoids can be used to screen the non-oncological drugs in vitro.

Conclusion: These identified old drugs could be repurposed in oncology and might be added as adjuvants and finally benefit patients with cancers.

Keywords: Drug repurposing; anti-cancer; drug screening; future direction of cancer; organoid; population cohort.

Publication types

  • Review

MeSH terms

  • Drug Evaluation, Preclinical
  • Drug Repositioning*
  • Humans
  • Neoplasms* / drug therapy
  • Treatment Outcome